Navamedic ASA appoints new CEO

Tom Rönnlund has been appointed new CEO of Navamedic ASA. Mr Rönnlund brings more than 17 years of business development and general management experience from the international healthcare industry to Navamedic.

Tom Rönnlund joins Navamedic from IMS Health Inc, a global analytics and technology services company focused on the healthcare sector, where he held the position of General Manager for the Nordic & Baltic Region. Prior to joining IMS Health, Tom has served in sales, marketing and general management roles with biopharmaceutical companies such as Bristol-Myers Squibb and Eli Lilly. He holds a degree in Business Administration and Economics from Stockholm University.

Tom Rönnlund assumes his new responsibilities at Navamedic on 18 May 2015.

"We are pleased that we have succeeded in recruiting Tom Rönnlund to Navamedic. He brings with him vast industry experience from Nordic and international markets and an impressive track record of business growth and general managemet. I am confident he will succeed in reinforcing the positive revenue and profit development the company is experiencing together with the Navamedic team. We thank Håkan Josephsson, who remains with the company, for his invaluable support as interim CEO" Navamedic Chairman Johan Reinsli said.

"I am very excited to join Navamedic and am looking forward to build on the great work by the current management team in focusing the product portfolio for continued growth and improved profitability as well as actively pursue portfolio expansion through partnerships and potential acquisitions" says Tom Rönnlund

For further information, please contact Navamedic's Chairman Johan Reinsli, telephone +47 91604145 or Tom Rönnlund, appointed CEO, telephone +46 768 564 735.

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 120 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).